α-甲酰-CoA消旋酶在乳腺癌中的表达及其意义

Expression of α-methylacyl-CoA-racemase in breast cancer and its significance

摘要: 目的:探讨α-甲酰-CoA消旋酶(AMACR/p504S)在乳腺癌中的表达状况及其临床病理意义。方法:选取73例乳腺癌及36例乳腺良性增生性病变,用免疫组化技术(S-P法)标记AMACR和ER、PR、c-erbB-2,光镜观察其表达情况并进行统计学处理。结果:AMACR在乳腺癌中表达的阳性率为86.3%,良性病变中为55.6%,两者差异有统计学意义(P<0.01)。AMACR在乳腺癌中的表达与组织学类型、分级以及ER、PR、c-erbB-2免疫表型等均无明显关系(P>0.05)。结论:AMACR不仅是前列腺癌的生物学标记,亦可作为乳腺癌病理诊断的参考。

Abstract: Objective: To investigate the expression of alpha-methylacyl-CoA-racemase(AMACR) in breast cancer and its clinico-pathological significance.Methods: AMACR and ER,PR,C-erbB-2 were detected in 73 cases of breast cancer and 36 cases of benign mammary lesions using immunohistochemical technique(S-P method),and the results were studied microscopically and statistically.Results: The positive rates of AMACR were 86.3% in breast cancer and 55.6% in benign mammary lesions,which had statistical significance(P<0.01).The expression of AMACR in breast cancer showed no difference among the typing,grading,and ER,PR,C-erbB-2 immunoplenotypes(P>0.05).Conclusions: AMACR is not only the biomarker of prostate cancer but can also be used in the pathological diagnosis of breast cancer.